PDS Biotechnology (PDSB) to Release Earnings on Thursday

PDS Biotechnology (NASDAQ:PDSB) is expected to be announcing its earnings results before the market opens on Thursday, March 27th. Analysts expect PDS Biotechnology to post earnings of ($0.31) per share for the quarter.

PDS Biotechnology Stock Down 3.6 %

Shares of PDS Biotechnology stock opened at $1.32 on Wednesday. The company has a fifty day moving average price of $1.41 and a 200 day moving average price of $2.18. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.55. PDS Biotechnology has a twelve month low of $1.13 and a twelve month high of $4.92. The stock has a market cap of $50.41 million, a price-to-earnings ratio of -1.14 and a beta of 1.68.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $21.00 price target on shares of PDS Biotechnology in a research report on Thursday, March 13th. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $11.67.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.